Teenage Cancer Trust's response to the Major Conditions Strategy

The Government’s interim Major Conditions Strategy was published today, outlining Government plans for cancer care along with five other conditions: cardiovascular diseases, including stroke and diabetes; chronic respiratory diseases; dementia; mental ill health; and musculoskeletal disorders. This is an interim plan, with the full plan expected to be published at a later date.  

Published:

Kate Collins, Chief Executive of Teenage Cancer Trust, said: “We welcome the publication of the interim Major Conditions Strategy, particularly the commitment to supporting faster diagnosis and exploring how people experiencing rare forms of cancer can be better supported – both of which are especially relevant to young people with cancer. 

“Teenagers and young adults with cancer have unique needs that differ from those of children and older adults, and require a specialist workforce with expertise as to how to meet them.  

“47% of teenagers and young adults diagnosed with cancer had to see their GP three or more times before referral – the most out of any age group. Cancer treatments can be less effective for young people as physical changes and rapid growth during puberty and young adulthood can negatively affect how the body metabolises chemotherapy, for example. And while clinical trials help researchers find new and better treatments, accessing them can be harder for young people as trials are not always designed with their needs in mind and sometimes have age limits which prevent young people from participating in them. 

“We are glad to see that the interim Major Conditions Strategy recognises that young people with cancer are often affected by rarer forms of the disease, and that this can create challenges with faster diagnosis. The full plan must be comprehensive in terms of how to meet these challenges, and Teenage Cancer Trust would welcome any opportunity to work with the Government and the NHS to ensure the unique needs if young people are met.”

We welcome the publication of the interim Major Conditions Strategy, particularly the commitment to supporting faster diagnosis and exploring how people experiencing rare forms of cancer can be better supported – both of which are especially relevant to young people with cancer. 

Kate Collins, Chief Executive

What have Teenage Cancer Trust recommended to the Government?

47%

The percentage of teenagers and young adults diagnosed with cancer who had to see their GP three or more times before referral – the most out of any age group

Next steps

Submitting responses to Government consultations gives Teenage Cancer Trust the opportunity advocate for the distinct needs of young people with cancer to be prioritised and addressed through Government policy. We will build on our evidence and recommendations in our ongoing and future campaigns, (including around access to expert psychological support, increasing the number of young people enrolled in clinical trials, and providing the teenage and young adult workforce with the resources and environment they need), and will continue to engage with Government, Parliamentarians and NHS leaders on the issues we have raised.  

References

52.9% of 16–24-year-olds spoke to a primary care professional only once or twice before their cancer diagnosis (NHS National Cancer Patient Experience Survey 2022):  https://www.ncpes.co.uk/latest-national-results/ 

Clinical pharmacology in the adolescent oncology patient: https://pubmed.ncbi.nlm.nih.gov/20439647/ 

Teenagers and young adults have lower rates of participation in clinical trials than younger children, for reasons including arbitrary age criteria and trials that are designed and communicated without accounting for the unique needs of the age group. See: Fern LA, Lewandowski JA, Coxon KM, Whelan J; National Cancer Research Institute Teenage and Young Adult Clinical Studies Group, UK. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 2014 Jul;15(8):e341-50. doi: 10.1016/S1470-2045(14)70113-5. PMID: 24988937.